SCHEMBL23218199

SCHEMBL23218199

CCOC(=O)Cc1cccc(F)c1OCc1coc2ccc(Br)cc12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 2/20 0.37
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
THRB P10828 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MTNR1A P48039 1/20 0.35
TP53 P04637 1/20 0.35
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853198 1.00 ALOX5 (0.38) ALOX5KMT2AMEN1POLBGAA
SCHEMBL23218680 0.90 THRB (0.41) ALOX5KMT2AMEN1POLBGAA
SCHEMBL29853258 0.90 THRB (0.41) ALOX5KMT2AMEN1POLBGAA
SCHEMBL29593139 0.89 MEN1 (0.37) ALOX5KMT2AMEN1POLBGAA
SCHEMBL23218492 0.89 MEN1 (0.37) ALOX5KMT2AMEN1POLBGAA
SCHEMBL23218697 0.88 MAPT (0.40) KMT2AMEN1POLBGAAMAPT
SCHEMBL29852861 0.88 MAOB (0.40) ALOX5KMT2AMEN1POLBGAA
SCHEMBL23218128 0.88 MAOB (0.40) ALOX5KMT2AMEN1POLBGAA
SCHEMBL29852717 0.88 MAPT (0.40) KMT2AMEN1POLBGAAMAPT
SCHEMBL23218939 0.87 NPC1 (0.36) ALOX5KMT2AMEN1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB ALOX5 317/4885KMT2A 4445/4885MEN1 1819/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALOX5 260/4885KMT2A 4835/4885MEN1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.